BSX · 8-K · 20260518PR000042
Guidance / Outlook
BOSTON SCIENTIFIC CORP · 2026-05-18 · Importance 51 · Surprise 60 · In source text
Boston Scientific expects the accelerated share repurchase to increase full-year 2026 adjusted earnings per share by $0.02. Management characterized the impact as accretive to the previously issued guidance dated April 22, 2026. The disclosed outlook effect is tied specifically to the ASR and its expected timing and settlement.
Key facts
- The expected net impact to adjusted earnings per share from the accelerated share repurchase in full year 2026 is $0.02. source
- Boston Scientific stated the $0.02 expected net impact to adjusted EPS from the ASR is accretive to its previously issued guidance on April 22, 2026. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| net_income | positive | committed | — | The expected net impact to adjusted earnings per share from the accelerated share repurchase in full year 2026 is $0.02. |